Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

  • Technology appraisal guidance
  • TA260
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance on this technology will be considered for review in June 2015. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
June 2012